Matthew Wilson Schwartz - 05 Apr 2022 Form 4 Insider Report for THERALINK TECHNOLOGIES, INC.

Role
Director
Signature
/s/ Matthew Wilson Schwartz
Issuer symbol
THER on OTC
Transactions as of
05 Apr 2022
Net transactions value
+$100,000
Form type
4
Filing time
26 Sep 2022, 16:19:52 UTC
Previous filing
21 Jun 2022
Next filing
26 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THER 8% Convertible Promissory Note Other $100,000 $100,000 05 Apr 2022 Common Stock 21,008,403 $0.004800 Direct F1, F2
transaction THER Warrant (right to buy) Other $0 +4,201,681 $0.000000 4,201,681 05 Apr 2022 Common Stock 4,201,681 $0.004800 Direct F3
transaction THER Stock Option (right to buy) Award $0 +5,191,080 $0.000000 5,191,080 16 Sep 2022 Common Stock 5,191,080 $0.003600 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased this promissory note from the corporation.
F2 Excludes shares issuable at the election of the Reporting Person upon conversion of accrued interest (both past and future) into shares of common stock.
F3 Granted to the Reporting Person as warrant coverage in connection with the convertible promissory note reported on this Table II.
F4 The stock options reported in this Form 4 will become exercisable upon the filing by the corporation of an S-8 registration statement covering its 2022 Equity Incentive Plan.